Video

Medicare Part D and Oncology

Author(s):

Lauren Santye, Assistant Editor

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Image Credit: shidlovski | stock.adobe.com
Related Content
Illustration from research for genomic medicine or gene therapy.
September 11th 2025

Navigating the Complex Landscape of Sickle Cell Gene Therapy: Operational Challenges and Collaborative Solutions

Luke Halpern, Assistant Editor
Pharmacy focus oncology Edition, radon and lung cancer
September 11th 2025

A Silent Killer: Unmasking Radon’s Link to Lung Cancer

Alexandra Gerlach, Associate Editor
Portrait of two smiling friendly multiethnical pharmacists working in modern pharmacy and making order for medicines in distribution company | Image Credit: sofiko14 | stock.adobe.com
September 11th 2025

Pharmacists at the Forefront: Expanding Roles in Innovative and Equitable Care

Mike Hennessy Jr, Chairman and CEO
Pharmacy Focus Oncology Edition Podcast
September 11th 2025

Protecting Community Oncology Practices in the Wake of the IRA

Alexandra Gerlach, Associate Editor
Non–small cell lung cancer (NSCLC) X-ray image -- Image credit: Sebastian Kaulitzki | stock.adobe.com
September 11th 2025

Zidesamtinib Shows Clinically Meaningful Activity, Durability in ROS1+ NSCLC

Gillian McGovern, Associate Editor
3D visualization of an antibody-drug conjugate. | Image Credit: © Alpha Tauri 3D - stock.adobe.com
September 11th 2025

Patritumab Deruxtecan Meets Primary End Point in ICARUS-BREAST01 Trial

Alexandra Gerlach, Associate Editor
© 2025 MJH Life Sciences

All rights reserved.